259
Participants
Start Date
December 21, 2021
Primary Completion Date
June 30, 2027
Study Completion Date
September 30, 2027
177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT
Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-edotreotide with a defined number of cycles will be administered.
CAPTEM (Capecitabine and Temozolomide)
Best standard of care treatment (investigator's choice \[from the protocol comparator list\]) according to individual risk-benefit assessment, institutional protocols, the local Prescribing Information, local regulations, or the local guidelines.
Amino-Acid Solution
The Amino-Acid Solution (AAS) to be used in this study will contain a mixture of lysine and arginine diluted in an electrolyte solution.
Everolimus
Best standard of care treatment (investigator's choice \[from the protocol comparator list\]) according to individual risk-benefit assessment, institutional protocols, the local Prescribing Information, local regulations, or the local guidelines.
FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)
Best standard of care treatment (investigator's choice \[from the protocol comparator list\]) according to individual risk-benefit assessment, institutional protocols, the local Prescribing Information, local regulations, or the local guidelines.
Royal North Shore Hospital, St Leonards
Memorial Sloan-Kettering Cancer Center, New York
ICAHN School of Medicine at Mount Sinai, Tish Cancer Institute, New York
Charite - University Hospital Berlin, Berlin
University Hospital Complex of Santiago (CHUS), Santiago de Compostela
European Institute of Oncology (IEO), IRCCS, Milan
Duke University School of Medicine, Duke Cancer Institute, Durham
University General Hospital Gregorio Maranon, Madrid
University Hospital 12 de Octubre, Department of Gastroenterology, Madrid
IUCT Oncopole - Institut Universitaire du Cancer de Toulouse, Toulouse
Central University Hospital de Asturias (HUCA), IUOPA - Universitary Institute of Oncology, Oviedo
Haut-Leveque Hospital, Department of Hepatogastroenterology and Digestive Tract Oncology, Pessac
H. Lee Moffitt Cancer Center & Research Institute, Tampa
Nantes University Hospital Center - Hotel Dieu Hospital, Nantes
University Duisburg-Essen, University Hospital Essen, Clinic for Nuclear Medicine, Essen
University and Polytechnic Hospital La Fe, Endocrinology, Valencia
University Hospital Bonn, Department of Nuclear Medicine, Bonn
Mayo Clinic - Rochester, Department of Oncology, Rochester
Washington University Alvin J. Siteman Cancer Center, St Louis
Edouard Herriot Hospital, Medical Oncology Unit, Lyon
Texas Oncology, Dallas
University of Texas MD Anderson Cancer Center, Houston
University of Colorado Hospital, Nuclear Medicine, Aurora
University of Utah, Huntsman Cancer Institute, Salt Lake City
University Hospital Erlangen, Department of Internal Medicine I - Endocrinology, Erlangen
Stanford Cancer Center, Palo Alto
"University Polyclinic Hospital G. Martino, Department of Biomedical Sciences, Dentistry and Morphological and Functional Imaging, Complex Operational Unit of Nuclear Medicine", Messina
All India Institute Of Medical Sciences, Nuclear Medicine, New Delhi
Fudan University Shanghai Cancer Center, Shanghai
Affiliated Hospital of Jiangnan University, Wuxi
Tata Memorial Hospital, Nuclear Medicine & Molecular Imaging, Mumbai
HCG Cancer Centre, Medical Oncology, Bangalore
Dana Farber Cancer Institute, Boston
Oregon Health and Science University, Portland
Fox Chase Cancer Center, Philadelphia
Peter MacCallum Cancer Centre, Melbourne
"University Polyclinic Foundation Agostino Gemelli - IRCCS, Complex Operative Unit of Medical Oncology", Rome
VU Medical Center (VUMC), Department of Medical Oncology, Amsterdam
Erasmus University Medical Center Rotterdam, Rotterdam
University Hospital Vall d'Hebron, Department of Medical Oncology, Barcelona
ICO Hospitalet, Catalan Institute of Oncology, Barcelona
King's College Hospital, London
ITM Solucin GmbH
INDUSTRY